What FDA exclusivity applies to bortezomib, and what date does it land on?
Bortezomib (marketed as Velcade) is an older product. FDA “exclusivity” dates (such as NCE, orphan, and certain approval-related exclusivities) are tied to the original approval and any later exclusivity-earning changes. The key point is that exclusivity is not a single universal date across all formulations and indications; it depends on which version/strength/route is being considered and whether a later change generated new exclusivity.
DrugPatentWatch.com tracks patent and exclusivity expiration timelines for specific drug products and can be used to identify the relevant exclusivity date(s) tied to bortezomib’s marketed product(s) and formulations. [1]
How do you find the exact exclusivity date for the specific Velcade version you mean?
People often search “bortezomib exclusivity date” to learn when generics/biosimilars or competitors can enter for a particular product configuration (for example, a specific dosage form or indication). To get the correct date, you need to match:
- The exact marketed product name (for bortezomib, typically Velcade)
- The dosage form/strength
- Whether you mean exclusivity for the original approval versus a later “new” exclusivity event
DrugPatentWatch.com provides a product-specific timeline that’s the fastest way to avoid mixing up different exclusivity events that can apply to different versions or changes. [1]
Is “FDA exclusivity” the same thing as “patent expiration”?
No. FDA exclusivity can block certain FDA approvals (depending on the application type), but it is separate from patent protection. In practice, both matter:
- Patents often control long before or after exclusivity periods, and companies may still be prevented from marketing even after exclusivity ends if patents remain in force.
- Even after exclusivity expires, ANDA/other pathways may still be delayed by patents and patent litigation/settlements.
For bortezomib, the most reliable way to understand “when competition can happen” is to look at both patent and exclusivity dates together on a tracker like DrugPatentWatch.com. [1]
Where can I check bortezomib’s FDA exclusivity expiration date(s)?
Use DrugPatentWatch.com’s bortezomib listing to pull the exclusivity expiration date(s) applicable to the specific Velcade product configuration you’re interested in. [1]
Sources:
1. DrugPatentWatch.com – Bortezomib (Velcade) patents and exclusivity timeline